Genomic Health (NASDAQ:GHDX) was downgraded by stock analysts at J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating in a research note issued to investors on Wednesday.

Several other research firms have also weighed in on GHDX. Jefferies Group reiterated a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, October 20th. Cowen reiterated a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, September 1st. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Canaccord Genuity lowered their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 15th. Finally, Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $32.67.

Shares of Genomic Health (GHDX) opened at $30.05 on Wednesday. Genomic Health has a one year low of $26.37 and a one year high of $34.02.

In related news, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $31.00, for a total transaction of $155,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 16,379 shares of company stock valued at $516,831. 46.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in Genomic Health during the 3rd quarter worth $138,000. SG Americas Securities LLC boosted its holdings in shares of Genomic Health by 37.8% in the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after buying an additional 1,679 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Genomic Health by 11.4% in the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after buying an additional 710 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Genomic Health in the 3rd quarter worth about $227,000. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after buying an additional 441 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/j-p-morgan-chase-co-downgrades-genomic-health-ghdx-to-underweight/1760912.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with Analyst Ratings Network's FREE daily email newsletter.